HBMN:SWX
HBM Healthcare Investments AG
233,00 CHF
arrow_upward
+1,30%(+3,00) 1D
29. tra, 13:05:06 GMT+2 · CHF
search
Svi simboli
1D
5D
1M
6M
GDD
1G
5G
MAKS
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za HBMN...
Otvori
233,50 CHF
Najviša
233,50 CHF
Najniža
230,50 CHF
Trž. kap.
1,57 mlr.
Prosj. kol.
6,47 tis.
Količina
1,16 tis.
Dividenda
3,22 %
Kvartalna dividenda
1,88 CHF
Datum nakon isplate dividende
2. srp 2025.
P/E omjer
6,49
52-tjed. najviša
245,50 CHF
52-tjed. najniža
157,40 CHF
EPS
35,93 CHF
Dionice u optjecaju
6,74 mil.
Vijesti
Iz izvora na cijelom webu
MarketBeat
·
prije 5 minuta
Short Interest in Viper Energy Inc. (NASDAQ:VNOM) Decreases By 26.0%
GuruFocus
·
prije 16 minuta
PureTech Health (PRTC) to Delist from Nasdaq, Remaining Listed o
Yahoo Finance
·
prije 33 minute
With EPS Growth And More, Camden National (NASDAQ:CAC) Makes An Interesting Case
Mining Weekly
·
prije 57 minuta
Rare Earths Americas announces IPO on NYSE
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
HBM Healthcare Investments AG – informacije
Glavni izvršni direktor-
Zaposlenici-
Osnovano12. srp 2001.
SjedišteZug, Zug, Švicarska
Sektor-
Web-lokacijahbmhealthcare.com
AI sadržaj može uključivati pogreške. Saznajte više